You are here

Peptide-Derived Orally-Active Kappa-Opioid Receptor Agonists for Peripheral Pain

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43DA036398-01A1
Agency Tracking Number: R43DA036398
Amount: $224,893.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NIDA
Solicitation Number: PA13-234
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
300 West Coleman Blvd. Suite 203
United States
DUNS: 831342022
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (843) 876-5092
Business Contact
Phone: (843) 860-8785
Research Institution

DESCRIPTION (provided by applicant): Treatment of peripheral pain of various origins remains a major unmet medical need, affecting tens to hundreds of millions of people nationwide at some time during their lives. Kappa-opioid agonists have been shown in peripheral pain models to be particularly efficacious but suffer from centrally mediated effects that have limited their development. Perhaps the most promising kappa-agonists under development are derivatives of the tetrapeptide D-Phe-D-Phe-D-Nle-D-Arg-NH2such as CR665, which exhibits high (but not absolute) peripheral to central (CNS) selectivity when administered IV. Clinical studies have shown significant benefit in patients with visceral and neuropathic pain; however, the compound is not active when administered orally which significantly limits its potential use as an analgesic for peripheral pain. As proof of concept, application of the Halimed Pharmaceuticals non- natural amino acid technology to CR665 produced derivatives that exhibit oral acti

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government